On the contrary, PAD4 overexpression can inhibit EMT by decreasing Elk1 expression, thereby inhibiting drug resistance.341 Zhou et al. demonstrated that PAD4 was decreased in adriamycin-resistant breast cancer. Here, PADI4 is linked to breast cancer.